Paroxysmal kinesigenic dyskinesia associated with a novel POLG variant
A case report
Yaping Zhou, MD, Jian Zhang, MD, Xiaoting Wang, MD, Qian Peng, MD, Xiuli Shang, PhD

Abstract
Introduction: Paroxysmal kinesigenic dyskinesia (PKD) is a rare neurological disease characterized by recurrent dyskinesia or choreoathetosis triggered by sudden movements. Pathogenic variants in PRRT2 are the main cause of PKD. However, only about half of clinically diagnosed PKD patients have PRRT2 mutations, indicating that additional undiscovered causative genes could be implicated. PKD associated with POLG variant has not been reported.

Patient concerns: A 14-year-old boy presented with a 2-month history of involuntary dystonic movements triggered by sudden activities. He was conscious during the attacks. Neurological examination, laboratory tests, brain magnetic resonance imaging (MRI), electroencephalogram (EEG) were all normal. Genetic analysis showed a novel variant of POLG (c.440G>T, p.Ser147Ile), which was considered to be a likely pathogenic variant in this case.

Diagnoses: The patient was diagnosed with PKD.

Interventions: Low dose carbamazepine was used orally for treatment.

Outcomes: The patient achieved complete resolution of symptoms without any dyskinesia during the 6-month follow up.

Conclusion: Our study identified the novel POLG variant (c.440G>T, p.Ser147Ile) to be a likely pathogenic variant in PKD.

Abbreviations: CBZ = carbamazepine, ECHS1 = enoyl CoA hydratase, short chain, 1, EEG = electroencephalogram, MRI = magnetic resonance imaging, mtDNA = mitochondrial DNA, PED = paroxysmal exercise-induced dyskinesias, PEO = progressive external ophthalmoplegia, PKD = paroxysmal kinesigenic dyskinesia, PNKD = paroxysmal non-kinesigenic dyskinesia, POLG1 = polymerase gamma 1, PRRT2 = proline-rich transmembrane protein 2, SCEH = short-chain enoyl-CoA hydratase protein.

Keywords: case report, movement disorder, paroxysmal kinesigenic dyskinesia, polymerase gamma variant

1. Introduction

Paroxysmal kinesigenic dyskinesia (PKD, OMIM #128200) is a rare neurological disease characterized by recurrent attacks of transient involuntary dystonia or choreoathetosis movements triggered by sudden activities.[1,2] The prevalence of PKD is about 1 in 150,000, and the average time to obtain a correct diagnosis is almost 5 years due to lack of recognition.[2,3] The commonly used diagnostic criteria of PKD was proposed by Bruno et al[3] in 2004, which is based on history, clinical observation, imaging, and laboratory test results. Genetic advances led to greater diagnostic certainty. In 2011, researchers founded the PRRT2 gene as a primary causative gene of PKD with an autosomal dominant inheritance pattern.[4] However, only about 50% of primary PKD patients have PRRT2 variants,[5,6] suggesting that some other genes may be responsible for PKD. Therefore, finding new pathogenic genes and variants may provide an unequivocal diagnosis of the disease. In the current study, we described a case of clinically diagnosed PKD patient with a novel heterozygous POLG variant, which may broaden the genetic spectrum of PKD.

2. Case report

A 14-year-old boy presented with a 2-month history of involuntary dystonic movements triggered by sudden activities after a period of physical rests. The involuntary movements last approximately 10 seconds. Attack frequency varies from about 20 times per day to once for a couple of weeks. Both sides of his body could be involved, accompanied by occasional spasmodic torticollis. Stress and anxiety can increase the likelihood of episodes. He was unable to control the attacks. His consciousness was unaffected during the process. He was previously healthy without known significant abnormalities during his birth and...
growth. His family history was not notable for involuntary movements, epilepsy, or other related diseases.

On physical examination, the vital signs were unremarkable and neurological examination was normal.

Laboratory test results were within normal limits, including routine serum tests, standard biochemistry profile, serum lactate concentration, ceruloplasmin, etc. Brain magnetic resonance imaging (MRI) was normal (Fig. 1). Electroencephalogram (EEG) was normal.

A diagnosis of PKD was concluded, and genetic analysis was carried out with a written informed consent obtained from his parents. High-throughput sequencing and Sanger sequencing were performed. Heterozygous variants were found in POLG (NM_002693.2, Exon2, c.440G>T, p.Ser147Ile) and PLA2G6 (NM_003560.3, Exon7, c.991G>T, p.Asp331Tyr) (Fig. 2). Both mutant alleles were inherited from his asymptomatic mother. The POLG variant (c.440G>T, p.Ser147Ile) located on the exonuclease domain, one of the important functional domains of
POLG1 protein, and may lead to infidelity of mitochondrial DNA (mtDNA) replication and proofreading errors.[7,8] This variant was novel and not registered in the following genetic public database: Human Gene Mutation Database (HGMD), ESP6500, 1000 Genomes Project, ClinVar, and dbSNP. The deleterious effect was predicted by multiple programs in silico, including PolyPhen-2, SIFT, MutationTaster, MutationAssessor, FATHMM, GERP, PhyloP, and SiPhy. The POLG variant was thus assigned as likely pathogenic according to the guidelines of the American College of Medical Genetics and Genomics.[9] The missense PLA2G6 variant (c.991G>T, p.Asp331Tyr) has been reported in Parkinsonism patients with an autosomal recessive inheritance pattern.[10] Thus, the PLA2G6 variant was considered less likely to be the causal gene in this case.

Oral carbamazepine (CBZ) 200 mg/d was used for treatment, and the dosages gradually reduced to 50 mg/d within 2 weeks. He achieved complete resolution of symptoms within 24 hours after he took medicine and reported no involuntary movements attacks when the dosage decreased to 50 mg/d. During the 6-month follow-up, the PKD episodes vanished entirely without a single attack since medicine use.

This study was approved by the Ethics Committee of the First Hospital of China Medical University and adhered to the tenets of the Declaration of Helsinki.

3. Discussion

The present study described a clinically diagnosed PKD patient harboring heterozygous variants in POLG and PLA2G6. No variant in PRRT2 was detected. The heterozygous POLG variant was novel and considered to be likely pathogenic in this case according to the guidelines of the American College of Medical Genetics and Genomics.[9] This patient meets the criteria for PKD associated with genes that may affect mitochondrial function. The identiﬁcation of additional PKD cases associated with POLG variants and further functional studies are warranted.

The pathophysiological mechanisms of POLG variant in PKD are unclear. Although multiple studies have been carried out on PKD, knowledge about the pathogenic mechanisms is limited.[24] Although the channelopathy hypothesis is prevailing in PKD, it is insufﬁcient to explain the pathophysiology fully.[25] A recent study reported a complicated case of PKD with SACS mutation.[26] The SACS gene encodes mitochondrial protein sacsin, and variants of SACS result in defects in mitochondrial dynamics. This study indicated that mitochondria might play a role in the pathophysiology of PKD. Our report could be the second research about PKD associated with genes that may affect mitochondrial function. The identiﬁcation of additional PKD cases associated with POLG variants and further functional studies are warranted.

The association between mitochondrial disorders and paroxysmal dyskinesias have also been reported in several other studies. Mutations in ECHS1 (enoyl CoA hydratase, short chain, 1, mitochondrial), encoding for the short-chain enoyl-CoA hydratase protein (SCEH), have been reported as a novel cause of paroxysmal exercise-induced dyskinesia (PED).[27,28] Paroxysmal
Almal non-kinesigenic dyskinesia (PNKD) can also occur in patients carrying variants in BCKD complex, which functioned as mitochondrial branched chain alpha ketoacid dehydrogenase kinase.[123]

Although most of the POLG-related disorders are autosomal dominant or autosomal recessive, variably penetrant and incompletely penetrant dominant variants have also been reported.[14,18,26–31] Burusnukul and de los Reyes[29] has reported a case of 2 half-siblings with heterozygous POLG variant (p. Gly517Val). The variant site located in the linker region between the exonuclease and polymerase domains of POLG1. The patients showed multiple symptoms, including early-onset seizures, myoclonus, hypotonia, and developmental delay, but their carrier mother was unaffected.[29] much as was the case in our study. Unfortunately, since limited family members of the patient were available in genetic analysis in our research, the exact inheritance pattern was unclear at this stage. These limitations also existed in previous similar studies.[26–28] Further clinical and biological researches are needed.

4. Conclusion

In conclusion, our study suggests a novel heterozygous POLG variant in a patient with PKD, which may expend the gene spectrum of PKD and help to diagnose precisely in PKD patients without PRRT2 mutations. The mitochondrial pathway may be a possible pathophysiology mechanism of PKD, and further functional analyses are needed.

Acknowledgments

The authors thank the Shenyang KingMed for Clinical Laboratory for the assistance in gene sequencing, as well as the patient and his parents for their participation in this study.

Author contributions

Formal analysis: Yaping Zhou.
Funding acquisition: Xiuli Shang.
Investigation: Yaping Zhou.
Project administration: Xiuli Shang.
Resources: Xiuli Shang.
Supervision: Xiuli Shang.
Validation: Xiuli Shang.
Visualization: Xiuli Shang.
Writing – original draft: Yaping Zhou.
Writing – review & editing: Yaping Zhou, Jian Zhang, Xiaoting Wang, Qian Peng, Xiuli Shang.

References

[1] Meneret A, Gaudebout C, Riant F, et al. PRRT2 mutations and paroxysmal disorders. Eur J Neurol 2013;20:872–8.
[2] van Roosendaal AF, Schade van Weestrum S, Velis DN, et al. The paroxysmal dyskinesias. Pract Neurol 2009;9:102–9.
[3] Bruno MK, Hallett M, Gwinn-Hardy K, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 2004;63:2280–7.
[4] Wang JL, Cao L, Li XH, et al. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias. Brain 2011;134(pt 12):3493–501.
[5] Becker F, Schubert J, Striano P, et al. PRRT2-related disorders: further PKD1 and ICCA cases and review of the literature. J Neurol 2013; 260:1234–44.
[6] McGovern EM, Roze E, Couinhan TJ. The expanding spectrum of paroxysmal movement disorders: update from clinical features to therapeutics. Curr Opin Neurol 2018;31:1491–7.
[7] Longley MJ, Nguyen D, Kunkel TA, et al. The fidelity of human DNA polymerase gamma with and without exconuclceolytic proofreading and the p55 accessory subunit. J Biol Chem 2001;276:38355–62.
[8] Wong LJ, Naviaux RK, Brunetti-Pierri N, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 2009;28:E150–72.
[9] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24.
[10] Guo YP, Tang BS, Guo JF. PL2G6-associated neurodegeneration (PLAN): review of clinical phenotypes and genotypes. Front Neurol 2018;9:1100.
[11] Li HE, Chen WJ, Ni W, et al. PRRT2 mutation correlated with phenotype of paroxysmal kinesigenic dyskinesia and drug response. Neurology 2013;80:1534–5.
[12] Houser MK, Soland VL, Bhataia KP, et al. Paroxysmal kinesigenic choreothetosis: a report of 26 patients. J Neurol 1999;246:120–6.
[13] Lecrenier N, Van Der Bruggen P, Fourny F. Mitochondrial DNA polymerases from yeast to man: a new family of polymerases. Gene 1997;185:147–52.
[14] Naviaux RK, Nguyen KV. POLG mutations associated with Alpers’ syndrome and mitochondrial DNA depletion. Ann Neurol 2004;55:706–12.
[15] Ropp PA, Copeland WC. Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma. Genomics 1996;36:449–58.
[16] Van Goethem D, Dernaut B, Loofgen A, et al. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001;28:211–2.
[17] Lamantea E, Tiraoti V, Bordoni A, et al. Mutations of mitochondrial DNA polymerase gamma are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann Neurol 2002;52:211–9.
[18] Horvath R, Hudson G, Ferrari G, et al. Phenotypic spectrum associated with mutations of the mitochondrial DNA polymerase gamma gene. Brain 2006;129(pt 7):1674–84.
[19] Da Pozzo P, Cardaiohi E, Rubegni A, et al. Novel POLG mutations and variable clinical phenotypes in 13 Italian patients. Neurol Sci 2017; 38:563–70.
[20] Tang S, Wang J, Lee NC, et al. Mitochondrial DNA polymerase gamma mutations: an ever expanding molecular and clinical spectrum. J Med Genet 2011;48:669–81.
[21] Blok MJ, van den Bosch BJ, Jongen E, et al. The unfolding clinical spectrum of POLG mutations. J Med Genet 2009;46:776–85.
[22] Hakonen AH, Heiniksen S, Juvonen V, et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive dystonia with ancient European origin. Am J Hum Genet 2005;77: 430–41.
[23] Nemeth AH. The genetics of primary dystonias and related disorders. Brain 2002;125(pt 4):695–721.
[24] Gardiner AR, Jaffer F, Dale RC, et al. The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain 2015;138(pt 12): 3567–80.
[25] Xu Z, Lim CK, Tan LCS, et al. Paroxysmal movement disorders: recent advances. Curr Neurol Neurosci Rep 2019;19:48.
[26] Lu Q, Shang L, Tan WT, et al. Complicated paroxysmal kinesigenic dyskinesia associated with SACS mutations. Ann Transl Med 2020; 8:8.
[27] Olgiati S, Skorvanek M, Quadri M, et al. Paroxysmal exercise-induced dystonia within the phenotypic spectrum of ECHS1 deficiency. Mov Disord 2016;31:1041–8.
[28] Mahajan A, Constantinoiu S, Sidropoulos C. ECHS1 deficiency-associated paroxysmal exercise-induced dyskinesias: case presentation and initial benefit of intervention. J Neurol 2017;264:185–7.
[29] Burusnukul P, de los Reyes EC. Phenotypic variations in 3 children with POLG1 mutations. J Child Neurol 2009;24:482–6.
[30] Copeland WC. The mitochondrial DNA polymerase in health and disease. Subcell Biochem 2010;50:211–22.
[31] Staropoli JF, Xin W, Barone R, et al. An atypical case of neuronal ceroid lipofuscinosis with co-inheritance of a variably penetrant POLG1 mutation. BMC Med Genet 2012;13:50.